Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2012
Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907).
Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 6 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Adherence to oral antineoplastic agents, an overview and meta-analysis.The oncologist · 2026Pooled it
- The lasting effects of resistance and endurance exercise interventions on breast cancer patient mental wellbeing and physical fitness.Scientific reports · 2022Pooled it
- Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.The Cochrane database of systematic reviews · 2021Pooled it
- A Systematic Review of Adherence to Oral Antineoplastic Therapies.The oncologist · 2016Pooled it
- Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review.Annals of oncology : official journal of the European Society for Medical Oncology · 2014Pooled it
- Oral cancer chemotherapy adherence and adherence assessment tools: a report from North Central Cancer Group Trial N0747 and a systematic review of the literature.Journal of cancer education : the official journal of the American Association for Cancer Education · 2013Pooled it
- Leveraging Mobile Health to Improve Capecitabine Adherence Among Women With Breast Cancer: A Pilot Randomized Controlled Trial.JCO oncology practice · 2024Trial
- An Automated Intervention Did Not Improve Adherence to Oral Oncolytic Agents While Managing Symptoms: Results From a Two-Arm Randomized Controlled Trial.Journal of pain and symptom management · 2018Trial
- Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG-ACRIN E2805 trial.Cancer medicine · 2021Article
- Adherence to oral anticancer chemotherapies and estimation of the economic burden associated with unused medicines.International journal of clinical pharmacy · 2020Article
- Oral antineoplastic agents: how do we care about adherence?British journal of clinical pharmacology · 2015Review
- Effect of age on drug metabolism in women with breast cancer.Expert opinion on drug metabolism & toxicology · 2015Review
- Patient-oncologist alliance, psychosocial well-being, and treatment adherence among young adults with advanced cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013Article
- Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice.Journal of the advanced practitioner in oncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundCyclophosphamide-methotrexate-5-fluorouracil (CMF) is often selected as adjuvant chemotherapy for older patients with early-stage breast cancer due to perceived superior tolerability. We sought to measure persistence with CMF, adherence to oral cyclophosphamide, and the association of these with toxic effects. PATIENTS AND
methodsCALGB 49907 was a randomized trial comparing standard chemotherapy (CMF or AC, provider/patient choice) with capecitabine in patients aged ≥65 with stage I-IIIB breast cancer. Those randomized to standard therapy and choosing CMF were prescribed oral cyclophosphamide 100 mg/m(2) for 14 consecutive days in six 28-day cycles. Persistence was defined as being prescribed six cycles of at least one of the three CMF drugs. Adherence was the number of cyclophosphamide doses that women reported they had taken divided by the number prescribed. Persistence and adherence were based on case report forms and medication calendars.
resultsOf 317 randomized to standard chemotherapy, 133 received CMF. Median age was 73 (range 65-88). Seventy-one percent submitted at least one medication calendar; 65% persisted with CMF. Non-persistence was associated with node negativity (P = 0.019), febrile neutropenia (P = 0.002), and fatigue (P = 0.044). Average adherence was 97% during prescribed cycles.
conclusionsSelf-reported adherence to cyclophosphamide was high, but persistence was lower, which may be attributable to toxic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.